The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The KRAS-variant and cetuximab response in RTOG 0522.
Joanne B. Weidhaas
Employment or Leadership Position - Mira Dx (I,U)
Consultant or Advisory Role - Mira Dx (U)
Stock Ownership - Mira Dx (B)
Jonathan Harris
No relevant relationships to disclose
Rita Axelrod
No relevant relationships to disclose
Adel K. El-Naggar
No relevant relationships to disclose
Anurag Singh
No relevant relationships to disclose
Thomas Galloway
No relevant relationships to disclose
David Raben
No relevant relationships to disclose
Dian Wang
No relevant relationships to disclose
Terence S. Herman
No relevant relationships to disclose
R. Jeffrey Lee
No relevant relationships to disclose
Rafael Ricardo Manon
No relevant relationships to disclose
Omar Yumen
No relevant relationships to disclose
Qiang Zhang
No relevant relationships to disclose
Christine H. Chung
No relevant relationships to disclose